T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dollar General
DG
|
+$1.37B |
| 2 |
Intel
INTC
|
+$1.28B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1B |
| 4 |
Nike
NKE
|
+$859M |
| 5 |
Uber
UBER
|
+$825M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.67B |
| 2 |
Amazon
AMZN
|
+$2.15B |
| 3 |
NVIDIA
NVDA
|
+$1.64B |
| 4 |
Humana
HUM
|
+$1.57B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1.33B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.09% |
| 2 | Healthcare | 15.81% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 10.82% |
| 5 | Communication Services | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Ardelyx
ARDX
$1.01B
| $14.4M | ﹤0.01% |
2,329,266
+597,099
| +34% | +$2.68M |
|
1027
Oscar Health
OSCR
$9.5B
| $14.4M | ﹤0.01% |
1,568,992
+704,913
| +82% | +$4.86M |
|
1028
Eastman Chemical
EMN
$8.29B
| $14.3M | ﹤0.01% |
158,724
-1
| -0% | -$80 |
|
1029
Universal Health Services
UHS
$10.2B
| $14.2M | ﹤0.01% |
93,449
+3,031
| +3% | +$408K |
|
1030
F5
FFIV
$24B
| $14.2M | ﹤0.01% |
79,481
+2,930
| +4% | +$478K |
|
|
PR
1031
Permian Resources
PR
$18B
| $14.2M | ﹤0.01% |
1,042,273
+907,737
| +675% | +$12.4M |
|
1032
Bio-Rad Laboratories Class A
BIO
$9.68B
| $14.2M | ﹤0.01% |
43,834
-2,113
| -5% | -$662K |
|
1033
Autoliv
ALV
$8.85B
| $14.1M | ﹤0.01% |
127,497
+6,837
| +6% | +$681K |
|
1034
C.H. Robinson
CHRW
$17.1B
| $13.9M | ﹤0.01% |
161,203
+1,645
| +1% | +$138K |
|
1035
Robert Half
RHI
$4.25B
| $13.9M | ﹤0.01% |
158,010
+5,560
| +4% | +$442K |
|
1036
Boston Properties
BXP
$10.8B
| $13.7M | ﹤0.01% |
194,753
+2,703
| +1% | +$160K |
|
1037
Pacira BioSciences
PCRX
$924M
| $13.6M | ﹤0.01% |
403,753
-5,236
| -1% | -$153K |
|
1038
Etsy
ETSY
$7.31B
| $13.5M | ﹤0.01% |
166,368
-2,431,901
| -94% | -$174M |
|
1039
Carlisle Companies
CSL
$15.2B
| $13.4M | ﹤0.01% |
42,952
+1,006
| +2% | +$277K |
|
1040
AtriCure
ATRC
$2.22B
| $13.3M | ﹤0.01% |
373,761
-60,722
| -14% | -$2.26M |
|
1041
Ambev
ABEV
$43.5B
| $13.3M | ﹤0.01% |
4,763,220
-232,300
| -5% | -$627K |
|
1042
Amylyx Pharmaceuticals
AMLX
$2.6B
| $13.2M | ﹤0.01% |
894,780
+870,560
| +3,594% | +$13.3M |
|
1043
Petrobras
PBR
$115B
| $13.2M | ﹤0.01% |
824,377
| – | – |
|
|
JNPR
1044
DELISTED
Juniper Networks
JNPR
| $13.1M | ﹤0.01% |
444,857
-8
| -0% | -$220 |
|
1045
Supernus Pharmaceuticals
SUPN
$2.78B
| $12.9M | ﹤0.01% |
445,316
-32,064
| -7% | -$850K |
|
|
NVEE
1046
DELISTED
NV5 Global
NVEE
| $12.9M | ﹤0.01% |
463,792
-198,900
| -30% | -$5.05M |
|
1047
Lyell Immunopharma
LYEL
$347M
| $12.9M | ﹤0.01% |
331,944
-2,366
| -0.7% | -$85.2K |
|
1048
KBR
KBR
$4.8B
| $12.8M | ﹤0.01% |
230,297
+5,444
| +2% | +$300K |
|
1049
LCI Industries
LCII
$2.6B
| $12.7M | ﹤0.01% |
101,144
-7,738
| -7% | -$890K |
|
1050
Magnolia Oil & Gas
MGY
$6.25B
| $12.6M | ﹤0.01% |
592,549
-1,948,273
| -77% | -$42.6M |
|
Similar funds
T. Rowe Price Associates's Q4 2023 Portfolio in Review
As of Q4 2023, T. Rowe Price Associates held 2,974 positions worth $744B, up 9.1% from $682B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates's Q4 2023 filing shows 92 new, 1,834 increased, 805 reduced and 67 closed positions. Its largest new stake was Canadian Natural Resources: 6,473,658 shares worth $212M. The largest sale was Microsoft, an estimated $2.67B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2023 buy was Canadian Natural Resources: 6,473,658 shares worth $212M.
- T. Rowe Price Associates added most to Dollar General in Q4 2023, an estimated $1.37B increase.
- T. Rowe Price Associates's biggest Q4 2023 reduction was Microsoft, cutting an estimated $2.67B.
- T. Rowe Price Associates fully exited Activision Blizzard in Q4 2023, selling an estimated $293M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $744B portfolio in Q4 2023.
- T. Rowe Price Associates opened 92 new positions and closed 67 in Q4 2023.
- T. Rowe Price Associates's portfolio value rose 9.1% quarter-over-quarter to $744B.
Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.